Every 8-K that Atricure (ATRC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ATRC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATRC filings page.
AtriCure, Inc. reported strong second quarter 2026 results, with worldwide revenue of $153.6 million, up 12.8% year over year (12.4% on a constant currency basis). U.S. revenue grew to $125.6 million, driven by cryoSPHERE MAX pain management probes, EnCompass clamps, and AtriClip FLEX-Mini and PRO-Mini devices; international revenue rose to $28.0 million.
Gross profit increased to $118.6 million and gross margin expanded to 77.2%, supported by favorable product and geographic mix and manufacturing efficiencies. The company generated income from operations of $9.7 million versus an operating loss a year earlier and net income of $9.0 million, or $0.18 per basic and diluted share, compared with a net loss of $6.2 million, or $0.13 per share, in second quarter 2025.
Adjusted EBITDA reached $27.3 million, up $11.9 million or 78% from the prior-year quarter, and cash generation was $21.6 million. For full year 2026, management projects revenue of $602 million to $610 million, adjusted EBITDA of $85 million to $89 million, net income per share of $0.05 to $0.13, and adjusted earnings per share of $0.24 to $0.32, with continued positive cash generation.
AtriCure, Inc. reported results of its 2026 Annual Meeting of Stockholders, where stockholders approved amendments to key equity compensation plans and all other management proposals. The 2023 Stock Incentive Plan share pool was raised from 4,500,000 to 6,000,000 shares of common stock, expanding capacity for future equity awards.
Stockholders also approved adding 750,000 shares to the 2018 Employee Stock Purchase Plan, ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, re-elected nine directors for one-year terms, and supported executive compensation in an advisory say-on-pay vote.
AtriCure, Inc. filed an amended report to correct and expand its 2026 financial guidance while releasing strong first quarter 2026 results. The company now projects full year 2026 revenue of $600 million to $610 million, adjusted EBITDA of $80 million to $82 million, adjusted earnings per share of $0.09 to $0.15, and net earnings per share of $0.00 to $0.04, with continued positive cash flow.
For the first quarter 2026, AtriCure generated revenue of $141.2 million, up 14.3% year over year, driven by 14.9% growth in U.S. sales and 11.5% international growth. Gross margin rose to 77.4%, income from operations improved to $0.5 million from a $6.0 million loss, and net income was $0.1 million compared to a $6.7 million loss a year earlier. Adjusted EBITDA nearly doubled to $17.1 million, reflecting higher sales and operating leverage.
AtriCure, Inc. reported solid first quarter 2026 results with continued growth and a return to profitability. Revenue reached $141.2 million, up 14.3% year over year, led by 14.9% growth in the U.S. driven by cryoSPHERE MAX, AtriClip FLEX-Mini and PRO-Mini, and the EnCompass clamp.
Gross margin improved to 77.4%, lifting income from operations to $0.5 million versus a $6.0 million loss a year ago. Net income was $0.1 million, or $0.00 per share, compared with a $0.14 loss per share. Adjusted EBITDA nearly doubled to $17.1 million, and management issued 2026 guidance for $600–$610 million revenue, $80–$82 million adjusted EBITDA, and adjusted EPS of $0.00–$0.04.
AtriCure, Inc. reported strong growth for the fourth quarter and full year 2025 while moving toward sustained profitability. Fourth quarter 2025 revenue was $140.5 million, up 13.1% year over year, with net income of $1.8 million and adjusted EBITDA of $19.9 million. Full year 2025 revenue reached $534.5 million, an increase of 14.9%, and gross margin improved to 75.0%. The company narrowed its net loss to $11.4 million while nearly doubling adjusted EBITDA to $61.8 million. Management projects 2026 revenue of $600–$610 million, full year positive net income, and adjusted EBITDA of $80–$82 million, with expected adjusted EPS between $0.09 and $0.15 and GAAP EPS between $0.00 and $0.04.
AtriCure, Inc. entered into a First Amendment to its credit agreement with JPMorgan Chase Bank and other lenders, extending the term of its asset-based revolving credit facility by three years. The amended credit agreement maintains an asset-based revolving credit facility of up to $125 million, with the option to increase commitments by up to $40 million, for a potential total of $165 million. A portion of the facility not exceeding $5 million is available for letters of credit, and swingline loans may be advanced at the Administrative Agent’s discretion. The amendment also reduces the overall interest rate on loans under the facility and removes the minimum utilization financial covenant. The facility is secured by a first priority security interest in substantially all borrower assets and is guaranteed by the company and its material domestic subsidiaries, and it will be used to finance working capital and general corporate purposes.
AtriCure, Inc. (ATRC) filed an Amendment No. 1 to its Form 8-K to add the required signature of a duly authorized representative. The amendment makes no other changes to the original report filed on October 29, 2025.
The company also noted it issued a press release regarding financial results for the third quarter ended September 30, 2025, and scheduled a conference call on October 29, 2025 at 4:30 p.m. Eastern Time. The press release is furnished as Exhibit 99.1.
AtriCure (ATRC) furnished an 8-K announcing third-quarter results communications. The company issued a press release covering financial results for the quarter ended September 30, 2025 and scheduled a conference call on October 29, 2025 at 4:30 p.m. Eastern Time to discuss the results. The press release is provided as Exhibit 99.1 and is incorporated by reference as furnished information.